ExodusPoint Capital Management’s Denali Therapeutics DNLI Stock Holding History

ExodusPoint Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,023,253	Closed	-$16.9M	–	1673
2025 Q4	$16.9M	Buy	+1,023,253	New	+$17.3M	0.13%	130
2023 Q4	–	Sell	-17,381	Closed	-$359K	–	1589
2023 Q3	$359K	Buy	+17,381	New	+$441K	﹤0.01%	1361
2023 Q2	–	Sell	-24,907	Closed	-$574K	–	1935
2023 Q1	$574K	Buy	+24,907	New	+$685K	﹤0.01%	1300
2022 Q4	–	Sell	-23,434	Closed	-$719K	–	1736
2022 Q3	$719K	Sell	23,434 -40,753	-63%	-$1.32M	0.01%	1240
2022 Q2	$1.89M	Buy	+64,187	New	+$1.68M	0.02%	801
2021 Q3	–	Sell	-20,959	Closed	-$1.64M	–	2231
2021 Q2	$1.64M	Buy	+20,959	New	+$1.3M	0.02%	770
2020 Q4	–	Sell	-5,723	Closed	-$205K	–	2041
2020 Q3	$205K	Sell	5,723 -9,914	-63%	-$299K	﹤0.01%	1466
2020 Q2	$378K	Buy	+15,637	New	+$368K	0.01%	1202
2019 Q4	–	Sell	-10,000	Closed	-$153K	–	1606
2019 Q3	$153K	Buy	+10,000	New	+$191K	0.01%	1179
2019 Q2	–	Sell	-13,770	Closed	-$320K	–	1150
2019 Q1	$320K	Buy	+13,770	New	+$288K	0.02%	451

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ExodusPoint Capital Management's DNLI Position: Q1 2026 in Review

ExodusPoint Capital Management sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 1,023,253 shares — an estimated $16.9M sold.

ExodusPoint Capital Management first reported a position in DNLI in Q1 2019 and held it in 10 quarters. The position peaked at $16.9M in Q4 2025. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

ExodusPoint Capital Management reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
ExodusPoint Capital Management sold 1,023,253 Denali Therapeutics shares in Q1 2026, an estimated $16.9M.
ExodusPoint Capital Management first reported a position in Denali Therapeutics in Q1 2019 and held it in 10 quarters.
ExodusPoint Capital Management's Denali Therapeutics position peaked at $16.9M in Q4 2025.
268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.